HOME >> BIOLOGY >> NEWS
New hope for patients with chronic lymphocytic leukemia

BUFFALO, NY -- Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December 1 issue of the Journal of Clinical Oncology.

"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.

Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.

In this phase II study the first to report clinical activity of lenalidomide in patients with CLL 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.

"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.


'"/>


4-Dec-2006


Page: 1

Related biology news :

1. Abnormal fat metabolism underlies heart problems in diabetic patients
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. Aggressive therapy best for certain AML patients
4. Investigating antibiotic use in acute care patients
5. CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell
6. Co-operation between GSF and clinic improves outlook for sarcoma patients
7. Skin rash actually signifies better outcomes for pancreatic and lung cancer patients
8. Study examines cause of hearing loss for patients with certain genetic disease
9. Stem cell procedure successfully treats amyloidosis patients
10. New research holds promise for protecting cancer patients against infertility
11. Europe struggles to meet the challenges posed by PGD patients travelling abroad

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today announced a ... Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of ... a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs ...
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While the ... economic downturn will only increase price pressures overall for the industry. The era of ... every product launch is critical. However, history shows that only a third of product ...
(Date:7/2/2020)... , ... July 01, 2020 , ... ... its phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory ... 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering patients ... million stem cells total, patients may choose which extremities they would like treated. , ... (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products has introduced ... materials for use with CRM, neurostimulation, vascular, and related devices. , Anomet ... design requirements, performance, and cost criteria; especially where solid wire is limited. Typical ...
(Date:7/31/2020)... ... , ... The SDX® Respiratory Gating System , trusted ... its 20th anniversary of worldwide use. Introduced in the US over the past ... of Pennsylvania, University of Michigan, University of Maryland, University of California San Francisco—and ...
Breaking Biology Technology:
Cached News: